Raptor Pharma weakness may provide buying opportunity, says Oppenheimer

theflyonthewall.com

After Raptor announced that the FDA had postponed its decision on approving Raptor's Procysbi for three months until April 30, 2013, Oppneheimer views the news as a short-term negative for the company but doesn't think it has any implication on the FDA's ultimate decision about Procysbi. The firm maintains an Outperform rating on Raptor.

Rates

View Comments (0)